. Corticosteroids-dose, mean (SD) 7.3 (4.2) a 6, p.52

. Igg, median (range) 6

. Igm, median (range) 0.49 (0.23-1.37

M. Sdai, 3) 38 patients 15.2 (10.8) 34 patients 29) 84 patients 17.4 (12.3) 68 patients 30.6 (12.0) 45 patients 18.0 (13.2) 35 patients 26.9 (13.8) 39 patients 16.6 (11.5) 33 patients - Decline in SDAI, mean (SD) - -15

D. Krause, B. Schleusser, G. Herborn, and R. Rau, Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis, Arthritis & Rheumatism, vol.18, issue.1, pp.14-21, 2000.
DOI : 10.1002/1529-0131(200001)43:1<14::AID-ANR3>3.0.CO;2-7

H. Choi, M. Hernán, J. Seeger, J. Robins, and F. Wolfe, Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study, The Lancet, vol.359, issue.9313, pp.1173-1180, 2002.
DOI : 10.1016/S0140-6736(02)08213-2

L. Jacobsson, C. Turesson, J. Nilsson, I. Petersson, E. Lindqvist et al., Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.66, issue.5, pp.670-675, 2007.
DOI : 10.1136/ard.2006.062497

M. Schoels, R. Knevel, D. Aletaha, J. Bijlsma, F. Breedveld et al., Evidence for treating rheumatoid arthritis to target: results of a systematic literature search, Annals of the Rheumatic Diseases, vol.69, issue.4, pp.638-681, 2010.
DOI : 10.1136/ard.2009.123976

S. Dadoun, N. Zeboulon-ktorza, C. Combescure, M. Elhai, S. Rozenberg et al., Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis, Joint Bone Spine, vol.80, issue.1, pp.29-33, 2013.
DOI : 10.1016/j.jbspin.2012.02.005

S. Gabriel, Why do people with rheumatoid arthritis still die prematurely?, Annals of the Rheumatic Diseases, vol.67, issue.Suppl 3, pp.30-34, 2008.
DOI : 10.1136/ard.2008.098038

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830861

S. Gabriel and K. Michaud, Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases, Arthritis Research & Therapy, vol.11, issue.3, p.229, 2009.
DOI : 10.1186/ar2669

M. Dougados, M. Soubrier, A. Antunez, P. Balint, A. Balsa et al., Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA), Annals of the Rheumatic Diseases, vol.71, issue.1, pp.62-70, 2014.
DOI : 10.1136/annrheumdis-2013-204223

A. Smitten, H. Choi, M. Hochberg, S. Suissa, T. Simon et al., The risk of hospitalized infection in patients with rheumatoid arthritis, J Rheumatol. mars, vol.35, issue.3, pp.387-93, 2008.

M. Doran, C. Crowson, G. Pond, O. Fallon, W. Gabriel et al., Predictors of infection in rheumatoid arthritis, Arthritis & Rheumatism, vol.140, issue.9, pp.2294-300, 2002.
DOI : 10.1002/art.10529

B. England, H. Sayles, K. Michaud, L. Caplan, L. Davis et al., Cause-Specific Mortality in Male US Veterans With Rheumatoid Arthritis, Arthritis Care & Research, vol.131, issue.Suppl, pp.36-45, 2016.
DOI : 10.1002/acr.22642

T. Sokka, B. Abelson, and P. T. , Mortality in rheumatoid arthritis: 2008 update, Clin Exp Rheumatol. oct, vol.26, issue.5, pp.35-61, 2008.

S. Naz and D. Symmons, Mortality in established rheumatoid arthritis, Best Practice & Research Clinical Rheumatology, vol.21, issue.5, pp.871-83, 2007.
DOI : 10.1016/j.berh.2007.05.003

J. Listing, K. Gerhold, and A. Zink, The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment, Rheumatology, vol.52, issue.1, pp.53-61, 2013.
DOI : 10.1093/rheumatology/kes305

A. Baillet, L. Gossec, L. Carmona, M. Wit, . De et al., Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative, Annals of the Rheumatic Diseases, vol.74, issue.2, pp.965-73, 2016.
DOI : 10.1136/annrheumdis-2016-209233

E. Loza, C. Lajas, J. Andreu, A. Balsa, I. González-Álvaro et al., Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis, Rheumatology International, vol.64, issue.5, pp.445-58, 2015.
DOI : 10.1007/s00296-014-3196-7

C. Roubille, V. Richer, T. Starnino, C. Mccourt, A. Mcfarlane et al., Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative, The Journal of Rheumatology, vol.42, issue.10, pp.1767-80, 2015.
DOI : 10.3899/jrheum.141112

W. Dixon, S. Suissa, and M. Hudson, The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses, Arthritis Research & Therapy, vol.13, issue.4, p.139, 2011.
DOI : 10.1136/ard.2009.125526

D. Lacaille, D. Guh, M. Abrahamowicz, A. Anis, and J. Esdaile, Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.44, issue.8, pp.1074-81, 2008.
DOI : 10.1002/art.23913

S. Ramiro, C. Gaujoux-viala, J. Nam, J. Smolen, M. Buch et al., Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.30, issue.(2), pp.529-564, 2014.
DOI : 10.1136/annrheumdis-2013-204575

T. Michaud, Y. Rho, T. Shamliyan, K. Kuntz, and H. Choi, The Comparative Safety of Tumor Necrosis Factor??Inhibitors in Rheumatoid Arthritis: A??Meta-analysis Update of 44 Trials, The American Journal of Medicine, vol.127, issue.12, pp.1208-1240, 2014.
DOI : 10.1016/j.amjmed.2014.06.012

J. Smolen, R. Landewé, F. Breedveld, M. Buch, G. Burmester et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update, Annals of the Rheumatic Diseases, vol.69, issue.(Suppl), pp.492-509, 2014.
DOI : 10.1136/annrheumdis-2013-204573

L. Campbell, C. Chen, S. Bhagat, R. Parker, and A. Östör, Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials, Rheumatology, vol.50, issue.3, pp.552-62, 2011.
DOI : 10.1093/rheumatology/keq343

C. Salliot, M. Dougados, and L. Gossec, Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials, Annals of the Rheumatic Diseases, vol.68, issue.1, pp.25-32, 2009.
DOI : 10.1136/ard.2007.083188

J. Gottenberg, P. Ravaud, T. Bardin, P. Cacoub, A. Cantagrel et al., Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry, Arthritis & Rheumatism, vol.39, issue.Suppl 3, pp.2625-2657, 2010.
DOI : 10.1002/art.27555

J. Salmon, J. Gottenberg, P. Ravaud, A. Cantagrel, B. Combe et al., Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry, Annals of the Rheumatic Diseases, vol.68, issue.(Suppl 10), pp.1108-1121, 2016.
DOI : 10.1136/annrheumdis-2015-207362

URL : https://hal.archives-ouvertes.fr/hal-01451900

J. Gottenberg, J. Morel, P. Ravaud, T. Bardin, P. Cacoub et al., OP0035???Tolerance of Rituximab, Abatacept and Tocilizumab in Common Practice: Analysis of the 3 Registries of the French Society of Rheumatology (Air, Ora and Regate), Annals of the Rheumatic Diseases, vol.74, issue.Suppl 2, pp.78-80, 2015.
DOI : 10.1136/annrheumdis-2015-eular.3807

M. Reff, K. Carner, K. Chambers, P. Chinn, J. Leonard et al., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood. 15 janv, vol.83, issue.2, pp.435-480, 1994.

M. Cragg, C. Walshe, A. Ivanov, and M. Glennie, The Biology of CD20 and Its Potential as a Target for mAb Therapy, Curr Dir Autoimmun, vol.8, pp.140-74, 2005.
DOI : 10.1159/000082102

B. Coiffier, C. Haioun, N. Ketterer, A. Engert, H. Tilly et al., Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study, Blood. 15 sept, vol.92, issue.6, pp.1927-1959, 1998.

J. Ioannidis, F. Karassa, E. Druyts, K. Thorlund, and E. Mills, Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales, Nature Reviews Rheumatology, vol.369, issue.11, pp.665-73, 2013.
DOI : 10.1038/nrrheum.2013.134

R. Mishra, V. Singh, and C. Pritchard, Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis, Rheumatology International, vol.25, issue.Suppl 46, pp.481-485, 2011.
DOI : 10.1007/s00296-009-1307-7

M. Genovese, F. Breedveld, P. Emery, S. Cohen, E. Keystone et al., Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients, Annals of the Rheumatic Diseases, vol.68, issue.12, pp.1894-1901, 2009.
DOI : 10.1136/ard.2008.101675

L. Harrold, G. Reed, C. Karki, R. Magner, A. Shewade et al., Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry, Arthritis Care & Research, vol.31, issue.4, 2016.
DOI : 10.1002/acr.22912

D. Ternant, T. Bejan-angoulvant, C. Passot, D. Mulleman, and G. Paintaud, Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis, Clinical Pharmacokinetics, vol.62, issue.Suppl 1, pp.1107-1130, 2015.
DOI : 10.1007/s40262-015-0296-9

A. College and . Rheumatology, European League against Rheumatism Preliminary Definition of Remission in Rheumatoid Arthritis for Clinical Trials, 3115717.

J. Smolen and D. Aletaha, Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants, Arthritis & Rheumatism, vol.61, issue.Suppl III, pp.43-52, 2011.
DOI : 10.1002/art.27740

I. Kushner, Regulation of the Acute Phase Response by Cytokines, Perspectives in Biology and Medicine, vol.36, issue.4, pp.611-633, 1993.
DOI : 10.1353/pbm.1993.0004

C. Richards, J. Gauldie, and H. Baumann, Cytokine control of acute phase protein expression, Eur Cytokine Netw. avr, vol.2, issue.2, pp.89-98, 1991.

I. Mcinnes, L. Thompson, J. Giles, J. Bathon, J. Salmon et al., Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study, Annals of the Rheumatic Diseases, vol.56, issue.4, pp.694-702, 2015.
DOI : 10.1136/annrheumdis-2013-204345

N. Nishimoto, Interleukin-6 in rheumatoid arthritis, Current Opinion in Rheumatology, vol.18, issue.3, pp.277-81, 2006.
DOI : 10.1097/01.bor.0000218949.19860.d1

J. Widdifield, S. Bernatsky, J. Paterson, N. Gunraj, J. Thorne et al., Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis, Arthritis Care & Research, vol.63, issue.Suppl, pp.353-61, 2013.
DOI : 10.1002/acr.21812

J. Curtis, F. Xie, L. Chen, J. Baddley, T. Beukelman et al., The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents, Annals of the Rheumatic Diseases, vol.70, issue.8, pp.1401-1407, 2011.
DOI : 10.1136/ard.2010.146365

M. Iguchi-hashimoto, M. Hashimoto, T. Fujii, M. Hamaguchi, M. Furu et al., The association between serious infection and disease outcome in patients with rheumatoid arthritis, Clinical Rheumatology, vol.71, issue.5, pp.213-221, 2016.
DOI : 10.1007/s10067-015-3143-3